Omeros (NASDAQ:OMER) Receives Hold Rating from Needham & Company LLC

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reaffirmed by equities researchers at Needham & Company LLC in a research note issued on Friday,Benzinga reports.

Other equities analysts have also issued reports about the company. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Tuesday. StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, April 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Up 0.5%

OMER opened at $3.95 on Friday. The company’s 50-day moving average price is $7.15 and its 200 day moving average price is $8.12. Omeros has a fifty-two week low of $3.00 and a fifty-two week high of $13.60. The firm has a market cap of $230.31 million, a price-to-earnings ratio of -1.71 and a beta of 2.42.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.08. During the same period in the prior year, the company posted ($0.15) earnings per share. Research analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Institutional Trading of Omeros

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in shares of Omeros by 121.3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Omeros during the fourth quarter worth $124,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Omeros by 12.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 4,401 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Omeros in the 4th quarter valued at $46,000. Finally, Cerity Partners LLC lifted its stake in Omeros by 9.9% during the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 2,600 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.